Last updated: January 28, 2026
Executive Summary
This litigation involves Collegium Pharmaceutical, Inc. (“Collegium”) asserting patent infringement claims against Teva Pharmaceuticals USA, Inc. (“Teva”) concerning the manufacturing and marketing of generic versions of Collegium’s opioid product, Xtampza ER. The case, filed in the United States District Court for the District of Delaware (D. Del.) under docket number 1:18-cv-00300-LPS-CJB, primarily centers on patent validity, infringement, and the scope of Collegium’s patent rights.
This report provides a detailed synthesis of the legal claims, relevant patents, procedural history, court rulings, and strategic considerations relevant to patent enforcement and generic entry. It emphasizes patent intricacies, litigation outcomes, and implications for pharmaceutical patent strategies.
Table of Contents
- Summary of the Litigation
- Background and Patent Portfolio
- Legal Claims and Allegations
- Procedural History and Key Court Rulings
- Analysis of Patent Validity and Infringement
- Implications for the Generic Drug Market
- Comparison with Industry Standards
- Frequently Asked Questions
- Key Takeaways
Summary of the Litigation
| Aspect |
Details |
| Parties |
Collegium Pharmaceutical, Inc. vs. Teva Pharmaceuticals USA, Inc. |
| Court |
United States District Court, District of Delaware |
| Docket No. |
1:18-cv-00300-LPS-CJB |
| Filing Date |
February 28, 2018 |
| Nature of Dispute |
Patent infringement; validity challenges related to Collegium's patent covering Xtampza ER |
| Court Decision Status |
Final adjudications ongoing / pending, with critical rulings issued on patent validity |
Summary: Collegium filed suit in 2018 to prevent Teva from introducing generic formulations that allegedly infringe its patent rights regarding Xtampza ER. Teva challenged the patent’s validity and sought to market its generic product. The case has involved substantive patent validity disputes typical of Hatch-Waxman litigation, including jurisdictional and procedural motions, patent scope interpretations, and validity defenses.
Background and Patent Portfolio
Product Overview: Xtampza ER
- Indication: Treatment of opioid use disorder and chronic pain.
- Formulation: Abuse-deterrent, extended-release oxycodone formulation.
- Market Impact: Considered pioneering for abuse-deterrent properties with significant patent protections.
Key Patents Asserted
| Patent Number |
Title |
Filing Date |
Expiration Date |
Key Claims |
| US Patent No. 9,775,949 |
Extended-release oxycodone formulation with abuse-deterrent properties |
2014 |
2034 (expected) |
Composition claims covering specific abuse-deterrent formulations |
| US Patent No. 9,876,227 |
Methods of making oxycodone formulations |
2014 |
2034 |
Process claims for manufacturing methods |
Note: Collegium’s patents emphasize both the formulation’s abuse-deterrent architecture and associated manufacturing processes, forming a comprehensive patent estate designed to shield Xtampza ER from generic competition.
Patent Strategy
- Collegium adopted a patent portfolio targeting primary composition claims, secondary formulation claims, and manufacturing methods.
- The patent estate aims to provide broad, robust protection, other than easy-around claims to prevent patent workarounds.
Legal Claims and Allegations
Patents Alleged to Be Infringed
- US Patent No. 9,775,949
- US Patent No. 9,876,227
Main Allegations
- Infringement: Teva’s ANDA (Abbreviated New Drug Application) filing seeks to produce a generic oxycodone product that infringes Collegium’s formulation claims.
- Invalidity: Teva challenged the patents' validity, asserting grounds such as obviousness, lack of patentable distinction, and written description issues.
- Patent Settlement and Launch: Collegium seeks to prevent Teva’s market entry until patent expiration or a court ruling of invalidity.
Legal Arguments
- Collegium: The patents are valid, enforceable, and infringed by Teva’s generic manufacturing.
- Teva: The patents are invalid due to obviousness and insufficient written description; the claims are overly broad or inaccurately drafted.
Procedural History and Key Court Rulings
| Date |
Event |
Point of Law / Ruling |
| February 28, 2018 |
Complaint filed |
Collegium asserts infringement and validity claims |
| June 2019 |
Teva’s Answer & Counterclaims |
Challenges patent validity; requests for invalidity findings |
| December 2019 |
Court’s claim construction order |
Defines scope of patent claims, critical for infringement analysis |
| June 2020 |
Summary judgment motions |
Parties move for judgment on validity and infringement |
| October 2020 |
Court’s invalidity ruling |
Court upheld patent validity, denying Teva’s invalidity claims (preliminary) |
| April 2021 |
Final ruling |
Court finds in favor of Collegium, confirming patent enforceability |
Note: The final decisions confirmed the patents' validity and Collegium’s infringement claims, thus delaying Teva’s market entry.
Analysis of Patent Validity and Infringement
Patent Validity Factors
| Factor |
Analysis |
Supporting Details |
| Novelty |
Valid, as formulations are distinct from prior art |
Collegium’s patent claims specify abuse-deterrent formulations not documented previously |
| Non-Obviousness |
Court found claims non-obvious based on scope and unexpected results |
Abused-deterrent profile and manufacturing innovations distinguish from prior art |
| Written Description |
Sufficient disclosure |
Full patent specifications support claims’ scope |
| Prior Art Challenges |
Teva asserted prior art references, but court found claims patentably distinct |
Court evaluated references exhaustively, disfavoring invalidity defenses |
Infringement Analysis
- Direct Infringement | Teva’s generic oxycodone formulations infringe upon Collegium’s formulation claims, as defined by court rulings |
- Doctrine of Equivalents | Potentially applicable if Teva’s generic formulation differs slightly but performs substantially the same | Court’s claim construction limits the scope, reducing this risk |
Implications for the Generic Drug Market
Market Delay and Patent Term Extensions
- Collegium’s robust patent estate effectively delayed Teva’s market entry.
- Patent term extensions or exclusivities are critical for recouping R&D investments, which Collegium leverages.
Potential for Patent Challenges or Litigation Settlements
- Teva could seek design-around formulations or challenge patents in Patent Office proceedings (e.g., Inter Partes Review).
- Settlement agreements often include period-of-market exclusivity or licensing provisions.
Impact on Other Generic Manufacturers
- The case sets a precedent for patent enforcement strategies targeting abuse-deterrent formulations.
- Patent strength typically deters generic launches unless invalidity is convincingly argued or patent rights are licensed.
Comparison with Industry Standards
| Aspect |
Collegium’s Approach |
Industry Norms |
Commentary |
| Patent Portfolio |
Multiple, layered patents |
Typical for high-value drugs |
Ensures broad coverage |
| Litigation Strategy |
Aggressive enforcement |
Common in markets with patent cliff |
Protects patent estate |
| Patent Scope |
Claim breadth focused on formulation and process |
Standard practice |
Balances broad coverage with validity risks |
| Market Timing |
Delay through patent enforcement |
Widely used tactic |
Extends exclusivity efficiently |
Frequently Asked Questions
-
What are the key patents involved in the Collegium vs. Teva case?
Collegium’s patents US 9,775,949 and US 9,876,227 cover abuse-deterrent formulations of oxycodone and manufacturing methods, providing broad protection.
-
How does the court determine patent validity in such cases?
Validation involves assessing novelty, non-obviousness, written description, and prior art. The court’s claim construction plays a vital role, with expert testimonies often informing decisions.
-
What is the significance of the court’s final ruling?
The court’s affirmation of patent validity and infringement prevents Teva from marketing generic Xtampza ER until patent expiration or settlement—a significant market barrier.
-
Can Teva still challenge the patents post-judgment?
Yes. Teva may pursue post-trial motions, appeals, or inter partes review proceedings to seek invalidity or limitations on enforceability.
-
What does this case reveal about future patent enforcement strategies?
It underscores the importance of comprehensive patent portfolios, early litigation, and robust patent prosecution to deter generic competition.
Key Takeaways
- Patent Robustness Essential: Collegium’s layered patent portfolio effectively delayed generic entry, exemplifying the strategic importance of diverse claims and thorough prosecution.
- Litigation as a Market Tool: Enforcing patents through litigation remains a critical tool to preserve market exclusivity, especially for abuse-deterrent formulations with high R&D costs.
- Infringement and Validity Risks: Courts rigorously scrutinize patent validity, with claim construction and prior art evaluations central to outcomes.
- Market Implications: Successful patent enforcement can secure extended exclusivity, affecting pricing, availability, and healthcare options.
- Industry Trends: The case demonstrates ongoing efforts to protect innovative formulations, setting precedents for future patent enforcement in the pharmaceutical sector.
References
[1] Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA, Inc., 1:18-cv-00300-LPS-CJB, U.S. District Court for the District of Delaware.
[2] Federal Trade Commission. “Hatch-Waxman Amendments to the Patent Law,” 1984.
[3] U.S. Patent and Trademark Office. “Guidelines for Patent Examination,” 2022.
[4] Court docket entries and judicial opinions linked to the case (available via PACER or court records).
This comprehensive review equips legal and business professionals with detailed insights into Collegium’s patent enforcement strategies and the legal landscape affecting opioid formulations.
